Candel Therapeutics (CADL) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.27
- Estimate
- -$0.31
- Surprise
- +12.4%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Candel Therapeutics (CADL) reported a narrower loss than forecast — adjusted EPS of -$0.27 against the -$0.31 estimate (a 12.4% beat on a still-unprofitable quarter).
Coverage in the report window
- Candel Therapeutics Shares Tumble 39% After-Hours: Here's Why — benzinga, 2026-11-13
- Candel Therapeutics Announces Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-12
- Candel Therapeutics Q3 EPS $(0.28) Beats $(0.35) Estimate — benzinga, 2026-11-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates CADL Sell at 5.2/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +12.4% surprise compares with a +15.2% four-quarter average.
What argues against it
- Concentration risk — Pipeline: aglatimagene
- Quality below floor (1.5 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin 1.6%), Material insider selling (8 sells, 0.11% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.39
- Price target
- $19.24
- Stop
- $7.80
- Upside to target
- +129.3%
- Reward-to-risk
- 8.6:1
Risk check: trading volume is running 1.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-13 — shown for context, not personalized investment advice.
CADL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $642.0M
- P/E (fwd)
- -13.4
- 52-week range
- $4.35–$14.00
- Off 52-week high
- 40.1%
- RSI (14)
- 53
- Volume vs avg
- 1.66×
- Score today
- 5.2/10